AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22839442 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol (2‐4 g/day)
Number of subjects: 120
Study 22839442 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol (1‐6 g/day orally)
Number of subjects: 120
Study 22839442 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet (1200‐1800 IU/day of vitamin D with multivitamins and from foodstuffs)
Number of subjects: 120
Study 22839442 — intervention group
Group type: COMPARATOR
Intervention: Placebo with diet control
Number of subjects: 120
Study 20421406 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir-ritonavir with efavirenz (3 tablets [600/150 mg], 4 capsules [533/133 mg], 2 tablets [400/100 mg] twice a day)
Number of subjects: 60
Study 20421406 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir-ritonavir with nevirapine (3 tablets [600/150 mg], 4 capsules [533/133 mg], 2 tablets [400/100 mg] twice a day)
Number of subjects: 60
Study 20421406 — intervention group
Group type: COMPARATOR
Intervention: lopinavir-ritonavir without NNRTIs (2 tablets [400/100 mg] twice a day)
Number of subjects: 60
Study 20421406 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir-ritonavir with efavirenz and nevirapine
Number of subjects: 60
Study 18760888 — intervention group
Group type: EXPERIMENTAL
Intervention: Entertainment-based decision aid for prostate cancer screening
Number of subjects: 450
Study 18760888 — intervention group
Group type: COMPARATOR
Intervention: Audiobooklet-control aid
Number of subjects: 450
Study 16086616 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 300 mg/day
Number of subjects: 26
Study 16086616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 12643293 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha2b plus ribavirin (1,000 to 1,200 mg per day)
Number of subjects: 52
Study 12643293 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha2b plus placebo
Number of subjects: 52
Study 9350362 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg morphine + 100 micrograms fentanyl
Number of subjects: 122
Study 9350362 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg morphine + 100 micrograms fentanyl
Number of subjects: 122
Study 9350362 — intervention group
Group type: COMPARATOR
Intervention: 2 mg morphine alone
Number of subjects: 122
Study 9350362 — intervention group
Group type: COMPARATOR
Intervention: 4 mg morphine alone
Number of subjects: 122
Study 2022769 — intervention group
Group type: EXPERIMENTAL
Intervention: Material A (soft polymer lining) worn for 14 days
Number of subjects: 10
Study 2022769 — intervention group
Group type: EXPERIMENTAL
Intervention: Material B (soft polymer lining) worn for 30 days
Number of subjects: 10
Study 2022769 — intervention group
Group type: COMPARATOR
Intervention: In vitro tests for both materials A and B
Number of subjects: 10
Study 6939318 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants (isocarboxazide, lithium citrate)
Number of subjects: 21
Study 6939318 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants (zimelidine, nomifensine)
Number of subjects: 21
Study 6939318 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants (imipramine oxide, mianserin)
Number of subjects: 21
Study 6939318 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants (maprotiline, nortriptyline, clomipramine, imipramine, amitriptyline)
Number of subjects: 21
Study 6939318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 31713697 — intervention group
Group type: EXPERIMENTAL
Intervention: Two miniplates
Number of subjects: 16
Study 31713697 — intervention group
Group type: EXPERIMENTAL
Intervention: One microplate and one miniplate
Number of subjects: 16
Study 31713697 — intervention group
Group type: COMPARATOR
Intervention: Control group (40 healthy adult volunteers)
Number of subjects: 16
Study 30782865 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based and cognitive interventions training, comprising three 4-hour sessions conducted every 2 weeks.
Number of subjects: 96
Study 30782865 — intervention group
Group type: COMPARATOR
Intervention: Waiting control group (no intervention initially).
Number of subjects: 96
Study 29024881 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal reflexology (six weekly 30-minute treatments)
Number of subjects: 90
Study 29024881 — intervention group
Group type: COMPARATOR
Intervention: Usual antenatal care only
Number of subjects: 90
Study 29024881 — intervention group
Group type: COMPARATOR
Intervention: Sham (footbath) treatments
Number of subjects: 90
Study 25943665 — intervention group
Group type: COMPARATOR
Intervention: HEAT
Number of subjects: 8
Study 25943665 — intervention group
Group type: EXPERIMENTAL
Intervention: HEAT + CO2
Number of subjects: 8
Study 25943665 — intervention group
Group type: COMPARATOR
Intervention: CON
Number of subjects: 8
Study 24431385 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% (160 mg)
Number of subjects: 60
Study 24431385 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 60
Study 22942337 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blocker (CCB)
Number of subjects: 4853
Study 22942337 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blocker (BB)
Number of subjects: 4853
Study 22942337 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 4853
Study 22942337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4853
Study 19542861 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic camera holder (RCH)
Number of subjects: 44
Study 19542861 — intervention group
Group type: COMPARATOR
Intervention: Human camera holder (HCH)
Number of subjects: 44
Study 17608775 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line treatment with a proton pump inhibitor (PPI), clarithromycin, and amoxicillin
Number of subjects: 0
Study 17608775 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth-containing quadruple regimens for 7-14 days
Number of subjects: 0
Study 17608775 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy for 10 days
Number of subjects: 0
Study 17608775 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI, levofloxacin, and amoxicillin for 10 days
Number of subjects: 0
Study 17608775 — intervention group
Group type: COMPARATOR
Intervention: Bismuth quadruple therapy
Number of subjects: 0
Study 15455739 — intervention group
Group type: EXPERIMENTAL
Intervention: Powered toothbrush
Number of subjects: 40
Study 15455739 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 40
Study 15455739 — intervention group
Group type: EXPERIMENTAL
Intervention: Both toothbrushes
Number of subjects: 40
Study 11596588 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil plus leucovorin
Number of subjects: 3351
Study 11596588 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil plus levamisole
Number of subjects: 3351
Study 11596588 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 3351
Study 11596588 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil plus leucovorin and fluorouracil plus levamisole combined
Number of subjects: 3351
Study 11596588 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil-based adjuvant therapy
Number of subjects: 3351
Study 11766711 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medicine
Number of subjects: 10
Study 11766711 — intervention group
Group type: COMPARATOR
Intervention: Sugar water (control)
Number of subjects: 10
Study 7831045 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Number of subjects: 74
Study 7831045 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU)
Number of subjects: 74
Study 2139916 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (KTZ) 400 mg/d
Number of subjects: 18
Study 2139916 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (KTZ) 800 mg/d
Number of subjects: 18
Study 631536 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-Dihydergot (2 x 0.5 mg DHE or 2 x 5000 IU of heparin)
Number of subjects: 454
Study 631536 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of DHE and heparin
Number of subjects: 454
Study 631536 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (3 x 0.5 g)
Number of subjects: 454
Study 631536 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 454
Study 31421677 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck extension group (E group)
Number of subjects: 65
Study 31421677 — intervention group
Group type: COMPARATOR
Intervention: Neutral position group (N group)
Number of subjects: 65
Study 27939124 — intervention group
Group type: EXPERIMENTAL
Intervention: Low thiamin concentration fish sauce (2 g/L)
Number of subjects: 276
Study 27939124 — intervention group
Group type: EXPERIMENTAL
Intervention: High thiamin concentration fish sauce (8 g/L)
Number of subjects: 276
Study 27939124 — intervention group
Group type: COMPARATOR
Intervention: Control fish sauce (no thiamin)
Number of subjects: 276
Study 25923435 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 1.0 mg/kg
Number of subjects: 50
Study 25923435 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 2.0 mg/kg
Number of subjects: 50
Study 25923435 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 3.0 mg/kg
Number of subjects: 50
Study 25923435 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 4.0 mg/kg
Number of subjects: 50
Study 25923435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 23422472 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS
Number of subjects: 40
Study 23422472 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 40
Study 21484393 — intervention group
Group type: EXPERIMENTAL
Intervention: bimanual spring (the objects were connected by a spring)
Number of subjects: 45
Study 21484393 — intervention group
Group type: COMPARATOR
Intervention: bimanual no-spring (the objects were not physically connected)
Number of subjects: 45
Study 21484393 — intervention group
Group type: COMPARATOR
Intervention: unimanual
Number of subjects: 45
Study 19534923 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy product consumption
Number of subjects: 7094
Study 19534923 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dairy product consumption)
Number of subjects: 7094
Study 17711706 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary adenovirus vector encoding hepatocyte growth factor (Ad(5)-HGF 5 x 10(9) pfu) plus stent implantation
Number of subjects: 18
Study 17711706 — intervention group
Group type: COMPARATOR
Intervention: Equal physiological saline plus stent implantation
Number of subjects: 18
Study 15536461 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam
Number of subjects: 61
Study 15536461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 11550835 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous fat graft implantation
Number of subjects: 186
Study 11550835 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fat graft)
Number of subjects: 186
Study 9505742 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.5 mm tracheal tube for men
Number of subjects: 0
Study 9505742 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.0 mm tracheal tube for women
Number of subjects: 0
Study 9505742 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.0 and 6.5 mm tracheal tubes
Number of subjects: 0
Study 9505742 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller size of tube
Number of subjects: 0
Study 9424863 — intervention group
Group type: EXPERIMENTAL
Intervention: Aneurysms with diameter 3‐4 cm
Number of subjects: 86
Study 9424863 — intervention group
Group type: EXPERIMENTAL
Intervention: Aneurysms with diameter 4‐5 cm
Number of subjects: 86
Study 9424863 — intervention group
Group type: EXPERIMENTAL
Intervention: Aneurysms with AP diameter bigger than 50 mm
Number of subjects: 86
Study 2699571 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste A (specific formulation not mentioned)
Number of subjects: 0
Study 2699571 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste B (specific formulation not mentioned)
Number of subjects: 0
Study 2699571 — intervention group
Group type: COMPARATOR
Intervention: Control group (dentists)
Number of subjects: 0
Study 1243528 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone decanoate plus cyclophosphamide
Number of subjects: 0
Study 1243528 — intervention group
Group type: EXPERIMENTAL
Intervention: Testololactone plus cyclophosphamide
Number of subjects: 0
Study 1243528 — intervention group
Group type: COMPARATOR
Intervention: Drostanolone plus cyclophosphamide
Number of subjects: 0
Study 30907290 — intervention group
Group type: EXPERIMENTAL
Intervention: Actor condition (animated actor communicating risk information)
Number of subjects: 0
Study 30907290 — intervention group
Group type: COMPARATOR
Intervention: Static visual formats or paragraph without actor
Number of subjects: 0
Study 28405611 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV2-GAD gene therapy
Number of subjects: 45
Study 26298615 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention: Counseling about etiologic factors and systemic nature of IC
Number of subjects: 19
Study 23927713 — intervention group
Group type: EXPERIMENTAL
Intervention: D222G variant in ICU patients (n=8/24, 33.3%)
Number of subjects: 24
Study 23927713 — intervention group
Group type: EXPERIMENTAL
Intervention: D222N variant in ICU patients (n=8/24, 33.3%)
Number of subjects: 24
Study 23927713 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU patients with D222G variant
Number of subjects: 24
Study 22256639 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular point sticking therapy
Number of subjects: 230
Study 22256639 — intervention group
Group type: COMPARATOR
Intervention: Routine complex treatment
Number of subjects: 230
Study 19332201 — intervention group
Group type: EXPERIMENTAL
Intervention: Occluded culprit artery
Number of subjects: 1957
Study 16698237 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime dosage administered by continuous infusion, individualized using a proposed formula based on creatinine clearance and target concentration at steady state.
Number of subjects: 60
Study 16698237 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime dosage administered by continuous infusion using the proposed formula.
Number of subjects: 60
Study 15142066 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba (n = 31)
Number of subjects: 66
Study 15142066 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 29)
Number of subjects: 66
Study 15142066 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba (n = 107/552)
Number of subjects: 66
Study 15142066 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 87/504)
Number of subjects: 66
Study 11320105 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone (two 2.5-mg patches per day)
Number of subjects: 67
Study 11320105 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 67
Study 9569785 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine‐containing varnish (Cervitec)
Number of subjects: 80
Study 9569785 — intervention group
Group type: COMPARATOR
Intervention: Placebo varnish
Number of subjects: 80
Study 7970646 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin supplement (containing 0.8 mg of folic acid)
Number of subjects: 5502
Study 7970646 — intervention group
Group type: COMPARATOR
Intervention: Trace-element supplement (containing copper, manganese, zinc, and a very low dose of vitamin C)
Number of subjects: 5502
Study 2835892 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.5 g dietary fibre supplement
Number of subjects: 62
Study 2835892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 30776393 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training
Number of subjects: 0
Study 29040040 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of carotid web at the symptomatic side
Number of subjects: 443
Study 29040040 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of carotid web at the asymptomatic side
Number of subjects: 443
Study 29040040 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographics of patients with symptomatic carotid web
Number of subjects: 443
Study 29040040 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors in patients with symptomatic carotid web
Number of subjects: 443
Study 29040040 — intervention group
Group type: EXPERIMENTAL
Intervention: Interobserver agreement in detection of carotid webs
Number of subjects: 443
Study 27875501 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training with ibuprofen (400 mg)
Number of subjects: 90
Study 27875501 — intervention group
Group type: COMPARATOR
Intervention: Stretching with placebo
Number of subjects: 90
Study 27875501 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 90
Study 25881903 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy screening
Number of subjects: 459814
Study 23279217 — intervention group
Group type: EXPERIMENTAL
Intervention: TZP-102 10 mg, 20 mg, 40 mg
Number of subjects: 92
Study 23279217 — intervention group
Group type: EXPERIMENTAL
Intervention: TZP-102 (any dose)
Number of subjects: 92
Study 23279217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 21639938 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational interventions consisting of a standardized teaching course aimed at doctors and nurses, lasting 6 hours split into three 2-hour blocks with subsequent monthly refresher courses.
Number of subjects: 150000
Study 21639938 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 150000
Study 18926856 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand movement program (experimental)
Number of subjects: 61
Study 18926856 — intervention group
Group type: COMPARATOR
Intervention: Read aloud program (control)
Number of subjects: 61
Study 16856219 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam (1.0 mg; 1.3 mg)
Number of subjects: 0
Study 16856219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12771597 — intervention group
Group type: EXPERIMENTAL
Intervention: New hub model (Segur-Lock) with antiseptic chamber filled with 3% iodinated alcohol
Number of subjects: 230
Study 12771597 — intervention group
Group type: COMPARATOR
Intervention: Standard Luer-lock connector (control group)
Number of subjects: 230
Study 10701059 — intervention group
Group type: EXPERIMENTAL
Intervention: 100,000 IU of vitamin D (treated group)
Number of subjects: 68
Study 10701059 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 68
Study 9377171 — intervention group
Group type: COMPARATOR
Intervention: Recombinant interleukin‐1 receptor antagonist (placebo-controlled)
Number of subjects: 59
Study 8383943 — intervention group
Group type: EXPERIMENTAL
Intervention: WIN 54954 (600 mg per dose, two doses on the first day followed by three doses on each of the subsequent 5 days)
Number of subjects: 39
Study 8383943 — intervention group
Group type: EXPERIMENTAL
Intervention: WIN 54954
Number of subjects: 39
Study 8383943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 3978010 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine-fentanyl mixture (200 micrograms fentanyl)
Number of subjects: 80
Study 3978010 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine-fentanyl mixture (50 micrograms fentanyl)
Number of subjects: 80
Study 3978010 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine-fentanyl mixture (100 micrograms fentanyl)
Number of subjects: 80
Study 3978010 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine-fentanyl mixtures (all doses)
Number of subjects: 80
Study 3978010 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine-fentanyl mixtures
Number of subjects: 80
Study 3978010 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fentanyl)
Number of subjects: 80
Study 28990633 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training focused on ankle strengthening and mobility, twice per week for 10 weeks.
Number of subjects: 93
Study 28990633 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise program).
Number of subjects: 93
Study 27107540 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 1327
Study 27107540 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 1327
Study 24584047 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 repetition maximum (5RM) strength exercise bouts
Number of subjects: 11
Study 24584047 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no prior strength exercise)
Number of subjects: 11
Study 22801062 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin (single intravenous dose at the time of LVP)
Number of subjects: 25
Study 22801062 — intervention group
Group type: COMPARATOR
Intervention: Vasoconstrictor combination of octreotide (20 mg intramuscular injection monthly) and midodrine (10 mg oral, 3 times/day)
Number of subjects: 25
Study 22801062 — intervention group
Group type: COMPARATOR
Intervention: Albumin group
Number of subjects: 25
Study 22801062 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasoconstrictor group
Number of subjects: 25
Study 20424399 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherers (n = 38) - patients with an increase >/= 18% in exercise from baseline to 6 months
Number of subjects: 71
Study 20424399 — intervention group
Group type: COMPARATOR
Intervention: Nonadherers (n = 33) - patients with no change or an increase in exercise of <18%
Number of subjects: 71
Study 20424399 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherers
Number of subjects: 71
Study 20424399 — intervention group
Group type: COMPARATOR
Intervention: Nonadherers
Number of subjects: 71
Study 18761243 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.5 microg/kg followed by 1 mg/kg of propofol
Number of subjects: 199
Study 18761243 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 0.5 microg/kg followed by 1 mg/kg of propofol
Number of subjects: 199
Study 16227663 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0